vs

Side-by-side financial comparison of INDEPENDENT BANK CORP (INDB) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

INDEPENDENT BANK CORP is the larger business by last-quarter revenue ($212.5M vs $151.7M, roughly 1.4× Tarsus Pharmaceuticals, Inc.). INDEPENDENT BANK CORP runs the higher net margin — 35.5% vs -5.5%, a 41.0% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 46.9%). INDEPENDENT BANK CORP produced more free cash flow last quarter ($75.5M vs $13.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 24.3%).

Independent Bank is a bank headquartered in Grand Rapids, Michigan. The bank has 62 branches, all of which are in Michigan.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

INDB vs TARS — Head-to-Head

Bigger by revenue
INDB
INDB
1.4× larger
INDB
$212.5M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+81.5% gap
TARS
128.4%
46.9%
INDB
Higher net margin
INDB
INDB
41.0% more per $
INDB
35.5%
-5.5%
TARS
More free cash flow
INDB
INDB
$62.6M more FCF
INDB
$75.5M
$13.0M
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
24.3%
INDB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
INDB
INDB
TARS
TARS
Revenue
$212.5M
$151.7M
Net Profit
$75.3M
$-8.4M
Gross Margin
Operating Margin
-5.3%
Net Margin
35.5%
-5.5%
Revenue YoY
46.9%
128.4%
Net Profit YoY
50.6%
63.8%
EPS (diluted)
$1.51
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INDB
INDB
TARS
TARS
Q4 25
$212.5M
$151.7M
Q3 25
$203.3M
$118.7M
Q2 25
$147.5M
$102.7M
Q1 25
$145.5M
$78.3M
Q4 24
$144.7M
$66.4M
Q3 24
$141.7M
$48.1M
Q2 24
$137.9M
$40.8M
Q1 24
$137.4M
$27.6M
Net Profit
INDB
INDB
TARS
TARS
Q4 25
$75.3M
$-8.4M
Q3 25
$34.3M
$-12.6M
Q2 25
$51.1M
$-20.3M
Q1 25
$44.4M
$-25.1M
Q4 24
$50.0M
$-23.1M
Q3 24
$42.9M
$-23.4M
Q2 24
$51.3M
$-33.3M
Q1 24
$47.8M
$-35.7M
Operating Margin
INDB
INDB
TARS
TARS
Q4 25
-5.3%
Q3 25
21.8%
-12.2%
Q2 25
44.6%
-21.6%
Q1 25
39.3%
-33.5%
Q4 24
-36.8%
Q3 24
39.0%
-52.3%
Q2 24
48.1%
-81.6%
Q1 24
45.5%
-136.5%
Net Margin
INDB
INDB
TARS
TARS
Q4 25
35.5%
-5.5%
Q3 25
16.8%
-10.6%
Q2 25
34.6%
-19.8%
Q1 25
30.5%
-32.1%
Q4 24
34.6%
-34.8%
Q3 24
30.3%
-48.7%
Q2 24
37.2%
-81.6%
Q1 24
34.8%
-129.4%
EPS (diluted)
INDB
INDB
TARS
TARS
Q4 25
$1.51
$-0.17
Q3 25
$0.69
$-0.30
Q2 25
$1.20
$-0.48
Q1 25
$1.04
$-0.64
Q4 24
$1.18
$-0.57
Q3 24
$1.01
$-0.61
Q2 24
$1.21
$-0.88
Q1 24
$1.12
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INDB
INDB
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$3.6B
$343.4M
Total Assets
$24.9B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INDB
INDB
TARS
TARS
Q4 25
$417.3M
Q3 25
$401.8M
Q2 25
$381.1M
Q1 25
$407.9M
Q4 24
$291.4M
Q3 24
$317.0M
Q2 24
$323.6M
Q1 24
$298.5M
Total Debt
INDB
INDB
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
INDB
INDB
TARS
TARS
Q4 25
$3.6B
$343.4M
Q3 25
$3.5B
$335.1M
Q2 25
$3.1B
$332.6M
Q1 25
$3.0B
$342.5M
Q4 24
$3.0B
$224.5M
Q3 24
$3.0B
$237.5M
Q2 24
$2.9B
$252.2M
Q1 24
$2.9B
$275.2M
Total Assets
INDB
INDB
TARS
TARS
Q4 25
$24.9B
$562.2M
Q3 25
$25.0B
$534.6M
Q2 25
$20.0B
$495.0M
Q1 25
$19.9B
$500.8M
Q4 24
$19.4B
$377.0M
Q3 24
$19.4B
$376.3M
Q2 24
$19.4B
$376.8M
Q1 24
$19.3B
$349.3M
Debt / Equity
INDB
INDB
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INDB
INDB
TARS
TARS
Operating Cash FlowLast quarter
$78.9M
$19.3M
Free Cash FlowOCF − Capex
$75.5M
$13.0M
FCF MarginFCF / Revenue
35.5%
8.6%
Capex IntensityCapex / Revenue
1.6%
4.2%
Cash ConversionOCF / Net Profit
1.05×
TTM Free Cash FlowTrailing 4 quarters
$239.0M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INDB
INDB
TARS
TARS
Q4 25
$78.9M
$19.3M
Q3 25
$52.2M
$18.3M
Q2 25
$106.7M
$-29.4M
Q1 25
$13.3M
$-20.7M
Q4 24
$42.9M
$-22.2M
Q3 24
$70.2M
$-8.7M
Q2 24
$65.6M
$-14.4M
Q1 24
$51.1M
$-37.8M
Free Cash Flow
INDB
INDB
TARS
TARS
Q4 25
$75.5M
$13.0M
Q3 25
$49.7M
$16.3M
Q2 25
$102.5M
$-30.4M
Q1 25
$11.3M
$-21.2M
Q4 24
$36.5M
$-22.3M
Q3 24
$64.4M
$-8.9M
Q2 24
$61.9M
$-15.4M
Q1 24
$46.7M
$-38.0M
FCF Margin
INDB
INDB
TARS
TARS
Q4 25
35.5%
8.6%
Q3 25
24.4%
13.8%
Q2 25
69.5%
-29.6%
Q1 25
7.8%
-27.1%
Q4 24
25.2%
-33.5%
Q3 24
45.4%
-18.6%
Q2 24
44.9%
-37.8%
Q1 24
34.0%
-137.5%
Capex Intensity
INDB
INDB
TARS
TARS
Q4 25
1.6%
4.2%
Q3 25
1.2%
1.6%
Q2 25
2.9%
1.0%
Q1 25
1.4%
0.8%
Q4 24
4.4%
0.1%
Q3 24
4.1%
0.6%
Q2 24
2.7%
2.5%
Q1 24
3.2%
0.6%
Cash Conversion
INDB
INDB
TARS
TARS
Q4 25
1.05×
Q3 25
1.52×
Q2 25
2.09×
Q1 25
0.30×
Q4 24
0.86×
Q3 24
1.64×
Q2 24
1.28×
Q1 24
1.07×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons